Showing results (41-50 of 143) with videos related to

Sort By:
Pageof 15
Cancer|March 20, 2002
A phase II study of neoadjuvant biochemotherapy for stage III melanomaPeter Gibbs, Clay Anderson, Nathan Pearlman, et al.
Immunotherapy|August 3, 2012
A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomesNicole Kounalakis, Dexiang Gao, Rene Gonzalez, et al.
Immunobiology|December 5, 2020
Myeloid arginase-1 controls excessive inflammation and modulates T cell responses in Pseudomonas aeruginosa pneumoniaDalia Haydar, Rene Gonzalez, Beth A Garvy, et al.
Breast Cancer Research : BCR|June 18, 2009
Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancerRuben Rene Gonzalez, Amber Watters, Yanbo Xu, et al.
Investigational New Drugs|October 16, 2009
A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanomaKarl D Lewis, Wolfram Samlowski, John Ward, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 15, 2014
High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicityOlivia R Deitcher, John Glaspy, Rene Gonzalez, et al.
Work (Reading, Mass.)|October 31, 2018
Strengths based rehabilitation assessment: Adapted Inventory of Virtues and StrengthsJeong Han Kim, Phillip S Keck, Megan C McMahon, et al.
Melanoma Research|March 15, 2019
Inflammatory side effects of BRAF and MEK inhibitorsAnna G Mackin, Paula E Pecen, Amanda L Dinsmore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanomaSteven O'Day, Rene Gonzalez, David Lawson, et al.
Cancer Investigation|August 17, 2005
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSFKarl D Lewis, Peter Gibbs, Steven O'Day, et al.
Pageof 15